What is EXOSYSTEMS?
Founded in 2017 and headquartered in Seoul, South Korea, EXOSYSTEMS operates at the intersection of advanced artificial intelligence and clinical healthcare. The company specializes in developing intelligent digital health platforms designed to enhance patient outcomes and streamline medical diagnostics. By integrating machine learning algorithms into traditional healthcare workflows, EXOSYSTEMS provides clinicians and patients with actionable data, effectively bridging the gap between raw medical information and therapeutic intervention. Its market position is characterized by a focus on high-growth, technology-enabled medical services, placing it at the forefront of the digital transformation currently reshaping the South Korean healthcare ecosystem.
How much funding has EXOSYSTEMS raised?
EXOSYSTEMS has raised a total of $3.9M across 1 funding round:
Series A
$3.9M
Series A (2021): $3.9M with participation from Korea Technology Finance, SBI Investment Korea, and Laguna Investment
Key Investors in EXOSYSTEMS
Korea Technology Finance
A specialized financial institution providing guarantees and credit evaluations to support technology-based startups and SMEs in their growth and innovation efforts.
SBI Investment Korea
A veteran venture capital and private equity firm with a broad mandate, focusing on high-growth sectors including biotechnology, healthcare, and information technology.
Laguna Investment
A specialized investment firm focused on identifying and capitalizing on distressed assets and high-value property opportunities through proprietary marketing systems.
What's next for EXOSYSTEMS?
With the successful closure of this major strategic investment, EXOSYSTEMS is poised to enter a new phase of operational expansion. The company is expected to prioritize the commercialization of its core AI platforms, targeting both domestic and international healthcare markets. Strategic focus will likely shift toward enhancing product efficacy through clinical validation and expanding its intellectual property portfolio. As the firm transitions from its initial development stage toward broader market penetration, the infusion of capital will be instrumental in scaling its infrastructure and talent acquisition. Investors remain optimistic that the company's robust technological foundation will facilitate long-term growth and sustainable competitive advantages in the rapidly evolving digital health sector.
See full EXOSYSTEMS company page
